A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1152 Given as a Continuous 48-hour Intravenous Infusion in Patients With Advanced Solid Malignancies

Inclusion Criteria:

- Histological or cytological confirmation of a solid, malignant tumour

- At least one measurable or non-measurable site of disease as defined by Response
Evaluation Criteria in Solid Tumors (RECIST) criteria.

Exclusion Criteria:

- Participation in an investigational drug study within the 21 days prior to therapy or
those who have not recovered from the effects of an investigational study drug

- Recent major surgery within 4 weeks prior to entry into the study